Back to companies

Incyte Corp: Overview

Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $329 per month (billed Annually)
Signup to View Free Sample

Incyte Corp (Incyte) is a biopharmaceutical company, which discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi. The company’s pipeline portfolio encompasses drugs for the treatment of lung cancer, graft versus host disease, non-small cell lung cancer, b-cell malignancies, solid tumors, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.

Headquarters United States of America

Address 1801 Augustine Cut Off, Wilmington, Delaware, 19803-4404


Telephone 1 302 4986700

No of Employees 2,094

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange INCY (NASD)

Revenue (2021) $3.0B 12% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX 420.8% (2021 vs 2020)

Market Cap* $16.6B

Net Profit Margin (2021) XXX 386.4% (2021 vs 2020)

* As of and is in US$

Explore premium data & analytics

460+

Catalyst Calendar

Proactively evaluate Incyte Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

400+

Clinical Trials

Determine Incyte Corp go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

350+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Incyte Corp’s relevant decision makers and contact details.

90+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

50+

Pipeline Drugs

Identify which of Incyte Corp’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

19+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

15+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Incyte Corp and assess market opportunity for new entrants with patient population 8-year forecasts.

5

Marketed Drugs

Understand Incyte Corp’s commercialized product portfolio to stay one step ahead of the market.

1

Medical Marketed Products

A database of medical devices currently for sale around the world. Devices that have been approved by a regulatory authority are included.

1

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Ruxolitinib Jakafi
Ponatinib Jakavi
Capmatinib Iclusig
XXX XXX
XXX XXX
XXX XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Regulatory Approval In May, the company and Eli Lilly received the US FDA approval for OLUMIANT (baricitinib) to treat hospitalized patients with COVID-19.
2022 Contracts/Agreements In April, the company and Maruho Co Ltd entered into an agreement for the development, manufacturing and commercialization of ruxolitinib cream for the treatment of autoimmune and inflammatory dermatology indications in Japan.
2021 Regulatory Approval In September, the company announced that the US FDA secured approval for its Jakafi to treat chronic graft-versus-host disease.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Incyte Corp F. Hoffmann-La Roche Ltd Merck & Co Inc Gilead Sciences Inc Amgen Inc
Headquarters United States of America Switzerland United States of America United States of America United States of America
City Wilmington Basel Kenilworth Foster City Thousand Oaks
State/Province Delaware - New Jersey California California
No. of Employees 2,094 100,920 68,000 14,400 24,200
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Net Income Growth

Image for loader
Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Herve Hoppenot Chairman Executive Board 2014 62
Christiana Stamoulis Executive Vice President; Chief Financial Officer Senior Management 2019 51
Steven H. Stein, M.D. Executive Vice President; Chief Medical Officer Senior Management 2015 55
Dashyant Dhanak, Ph.D. Executive Vice President; Chief Scientific Officer Senior Management 2018 61
Michael Morrissey Executive Vice President; Head - Global Technical Operations Senior Management 2016 58
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe

Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer